Grace Therapeutics, Inc. (GRCE) Operating cash flow 2020–2026
Grace Therapeutics, Inc. (GRCE) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$8.9MFY2026 · since FY2020: -$23.0M → -$8.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$8.9M | +40.5% |
| FY2025 | -$14.9M | -20.8% |
| FY2024 | -$12.3M | +22.5% |
| FY2023 | -$15.9M | +7.7% |
| FY2022 | -$17.2M | -20.4% |
| FY2021 | -$14.3M | +37.6% |
| FY2020 | -$23.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice